Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities litigation

Capricor Deramiocel Securities Fraud Class Action

Analysis based on 267 articles · First reported Aug 10, 2026 · Last updated Sep 22, 2026

Sentiment
-25
Attention
4
Articles
267
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The litigation and the underlying FDA disclosure event have already driven a roughly 64% single-day collapse in Capricor shares, and the pending class action keeps a material overhang on the stock and on sentiment toward clinical-stage biotechnology names with disputed statistical analysis plans. The extended PDUFA date to November 22, 2026 shifts the binary regulatory catalyst for Capricor further out, sustaining elevated volatility and headline risk for the sector.

biotechnology pharmaceuticals legal services

Paragon Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers are defendants in a securities fraud class action pending in the United States — United States District Court for the Southern District of California, captioned Nkamga v. Paragon Therapeutics, Inc., et al., No. 26-cv-04385. The class period runs from December 17, 2025 to July 26, 2026. The complaint alleges that Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for its lead product candidate Deramiocel, a cell therapy for Duchenne muscular dystrophy, and that the United States — Food and Drug Administration had not agreed to those changes before Capricor resubmitted its Biologics License Application. On July 27, 2026, the FDA released briefing documents ahead of its July 29 advisory committee meeting stating that the final SAP version was not submitted for review prior to BLA submission and was not agreed upon, that the conversion of raw change to percent change and back was not scientifically justified, and that the benefit-risk assessment for Deramiocel appeared unfavorable in the absence of evidence of effectiveness. Capricor shares fell $12.70, or 64%, to close at $7.00 on July 27, 2026. On July 29, 2026 the advisory committee met and, according to Medscape, voted 9-3 that available evidence does not support efficacy of Deramiocel for DMD-associated cardiomyopathy; shares fell a further 36% to $4.19 on July 30, 2026. On August 24, 2026 Capricor announced that the FDA extended the PDUFA target action date for the Deramiocel BLA from August 22, 2026 to November 22, 2026, classifying the submission as a major amendment. Numerous law firms have issued notices reminding investors of the September 28, 2026 lead plaintiff deadline.

100 Kahn Swick & Foti filed class action lawsuit Paragon Therapeutics
100 Kessler Topaz Meltzer & Check filed class action lawsuit Paragon Therapeutics
100 DJS Law Group filed class action Paragon Therapeutics
100 Paragon Therapeutics faced securities class action
100 Kessler Topaz Meltzer & Check filed class action lawsuit Paragon Therapeutics
100 Kahn Swick & Foti filed class action lawsuit Paragon Therapeutics
100 DJS Law Group filed class action Paragon Therapeutics
99 Rosen Law Firm filed class action lawsuit Paragon Therapeutics
99 Robbins LLP filed class action Paragon Therapeutics
+ 92 more actions View on Dashboard
priv
Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Importance 100.0 Sentiment -55.0
govactor
The FDA's July 27, 2026 briefing documents and July 29 advisory committee meeting triggered the stock collapse underlying the lawsuit, and its extension of the Deramiocel PDUFA date to November 22, 2026 keeps the review active.
Importance 70.0 Sentiment 0.0
per
Nkamga is the named plaintiff in the class action lawsuit against Capricor. The individual represents the class of investors who suffered losses during the class period.
Importance 30.0 Sentiment 0.0
govactor
The court is the venue for the pending class action Nkamga v. Paragon Therapeutics, Inc., et al., No. 26-cv-04385, and will rule on the September 28, 2026 lead plaintiff appointment.
Importance 30.0 Sentiment 0.0
per
Capricor's CEO, whose positive statements about HOPE-3 and Deramiocel are cited in the complaint as materially misleading.
Importance 25.0 Sentiment -30.0
govactor
The SEC is the regulator whose Rule 10b-5 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 form the basis of the securities fraud claims against Capricor.
Importance 25.0 Sentiment 0.0
priv
The firm announced the class action against Capricor and is soliciting investors for lead plaintiff appointment by September 28, 2026.
Importance 20.0 Sentiment 0.0
priv
The firm announced the filing of the class action and detailed the FDA briefing documents and stock declines.
Importance 20.0 Sentiment 0.0
priv
The firm reminded purchasers of Capricor securities of the September 28, 2026 lead plaintiff deadline.
Importance 20.0 Sentiment 0.0
priv
The firm notified investors of the class action and the September 28, 2026 lead plaintiff deadline.
Importance 20.0 Sentiment 0.0
priv
The firm announced the opportunity for investors with losses to lead the securities fraud class action before the September 28, 2026 deadline.
Importance 20.0 Sentiment 0.0
priv
The firm announced the class action and the September 28, 2026 lead plaintiff deadline.
Importance 20.0 Sentiment 0.0
priv
The firm notified investors of the September 28, 2026 deadline and highlighted the FDA's extension of the BLA review period.
Importance 20.0 Sentiment 0.0
priv
The firm announced the class action and detailed the 64.5% stock drop and the advisory committee vote.
Importance 20.0 Sentiment 0.0
priv
Cantor Fitzgerald analyst Kristen Kluska published an investor note stating the FDA briefing documents paint an ugly picture and raise concerns about the integrity of data collection, a view cited in the complaint.
Importance 20.0 Sentiment 0.0
+ 42 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.